van der Schoot S C, Vainchtein L D, Nuijen B, Gore A, Mirejovsky D, Lenaz L, Beijnen J H
Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, The Netherlands.
Pharmazie. 2008 Nov;63(11):796-805.
Two new bladder instillations of the investigational anticancer agent EO-9 containing 2-hydroxypropyl-beta-cyclodextrin (HP beta CD) and the alkalizers sodium bicarbonate (NaHCO3) and tri(hydroxymethyl)aminomethane (Tris) were developed. During the stability study of these freeze-dried products, formation of new degradation products was seen. We have characterized these products by high performance liquid chromatography in combination with photodiode array detection and mass spectrometry. In total, five new degradation products were identified of which three were detected in both freeze-dried products and two only in the freeze-dried product composed of EO-9/HP beta CD/NaHCO3. Furthermore, the purity profile of two lots of EO-9 drug substance was investigated. Five, probably synthetic intermediates were found. However, the amount of total impurities was very small for both lots of drug substance and below acceptable international limits for pharmaceutical use.
研发了两种新的膀胱灌注制剂,其中含有研究用抗癌药物EO-9、2-羟丙基-β-环糊精(HPβCD)以及碱化剂碳酸氢钠(NaHCO₃)和三(羟甲基)氨基甲烷(Tris)。在对这些冻干产品的稳定性研究过程中,发现了新的降解产物。我们通过高效液相色谱结合光电二极管阵列检测和质谱对这些产物进行了表征。总共鉴定出五种新的降解产物,其中三种在两种冻干产品中均被检测到,另外两种仅在由EO-9/HPβCD/NaHCO₃组成的冻干产品中被检测到。此外,还对两批EO-9原料药的纯度概况进行了研究。发现了五种可能的合成中间体。然而,两批原料药的总杂质含量都非常低,低于国际药品使用可接受限度。